Literature DB >> 1682035

Accumulation of genetic alterations and progression of primary breast cancer.

T Sato1, F Akiyama, G Sakamoto, F Kasumi, Y Nakamura.   

Abstract

In order to detect common regions of deletion, 219 breast tumors were examined for loss of heterozygosity at several loci on chromosomes 3p, 16q, and 17 by restriction fragment length polymorphism analysis. Allelic deletions of loci on chromosomes 3p, 13q, 16q, and 17, and amplification of the erbB2 oncogene, were analyzed and compared with histopathological and clinical features. Common regions of deletion were detected within chromosomal bands 3p13-14.3, 16q22-23, 17p13 (two separated loci), and 17q21. Concordant losses of alleles on chromosomes 3p, 13q, 16q, 17p, and 17q were observed. A significant association was detected between loss of heterozygosity on chromosomes 17p and 17q and amplification of the erbB2 oncogene (17p, P = 0.000721, by Fisher's exact test; 17q, P less than 0.001, chi 2 = 12.135). Furthermore, tumors showing highly malignant phenotypes had accumulated more genetic changes at the loci studied than those having less malignant phenotypes on the basis of histopathological classification, lymph node metastasis, and tumor size. These results suggested that accumulation of genetic alterations, including loss of function of tumor suppressor genes on chromosomes 3p, 13q, 16q, and 17, and amplification of the erbB2 oncogene, may contribute to tumor development and/or progression in primary breast cancer.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1682035

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  56 in total

1.  Multiplex genotype analysis of invasive carcinoma and accompanying proliferative lesions microdissected from breast tissue.

Authors:  X Cui; H Feiner; Z Lin; H Li
Journal:  J Mol Diagn       Date:  2000-02       Impact factor: 5.568

2.  Low Frequency Loss of Heterozygosity in the BRCA1 Region in Japanese Sporadic Breast Cancer.

Authors: 
Journal:  Breast Cancer       Date:  1996-12-20       Impact factor: 4.239

3.  Detection of numerical and structural alterations and fusion of chromosomes 16 and 1 in low-grade papillary breast carcinoma by fluorescence in situ hybridization.

Authors:  H Tsuda; T Takarabe; N Susumu; J Inazawa; S Okada; S Hirohashi
Journal:  Am J Pathol       Date:  1997-10       Impact factor: 4.307

4.  High-resolution chromosome 3p allelotyping of breast carcinomas and precursor lesions demonstrates frequent loss of heterozygosity and a discontinuous pattern of allele loss.

Authors:  A Maitra; I I Wistuba; C Washington; A K Virmani; R Ashfaq; S Milchgrub; A F Gazdar; J D Minna
Journal:  Am J Pathol       Date:  2001-07       Impact factor: 4.307

5.  Closing in on a breast cancer gene on chromosome 17q.

Authors:  J M Hall; L Friedman; C Guenther; M K Lee; J L Weber; D M Black; M C King
Journal:  Am J Hum Genet       Date:  1992-06       Impact factor: 11.025

6.  Decreased expression of the DCC gene in human breast carcinoma.

Authors:  K Wakita; N Kohno; Y Sakoda; Y Ishikawa; M Sakaue
Journal:  Surg Today       Date:  1996       Impact factor: 2.549

7.  Loss of heterozygosity on chromosome 11p13 in primary bladder carcinoma.

Authors:  R Shipman; P Schraml; M Colombi; G Raefle; C U Ludwig
Journal:  Hum Genet       Date:  1993-06       Impact factor: 4.132

Review 8.  Molecular cloning of BRCA1: a gene for early onset familial breast and ovarian cancer.

Authors:  A M Bowcock
Journal:  Breast Cancer Res Treat       Date:  1993-11       Impact factor: 4.872

9.  Allelotyping of butadiene-induced lung and mammary adenocarcinomas of B6C3F1 mice: frequent losses of heterozygosity in regions homologous to human tumor-suppressor genes.

Authors:  R W Wiseman; C Cochran; W Dietrich; E S Lander; P Söderkvist
Journal:  Proc Natl Acad Sci U S A       Date:  1994-04-26       Impact factor: 11.205

Review 10.  Anti-invasion drugs.

Authors:  R B Dickson; M D Johnson; M Maemura; J Low
Journal:  Breast Cancer Res Treat       Date:  1996       Impact factor: 4.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.